How effective is enzalutamide? What is the efficacy and clinical performance in patients with prostate cancer?

Enzalutamide is an androgen receptor inhibitor that is widely used to treat castration-resistant prostate cancer (CRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have shown that the drug can effectively inhibit the androgen receptor signaling pathway, delay disease progression, and significantly improve patients' progression-free survival (PFS) and overall survival (OS). In the PREVAIL clinical trial, patients with metastatic castration-resistant prostate cancer (mCRPC) who had not received chemotherapy had a reduced risk of disease progression with enzalutamide81%, the overall survival was extended to 35.3 months, compared with 31.3 months in the placebo group, showing a significant survival benefit.

Enzalutamide also shows good efficacy in prostate cancer patients who have received chemotherapy. In the AFFIRM clinical trial, patients treated with enzalutamide had a 37% reduction in the risk of death compared with the placebo group, and the median survival period was extended from 13.6 months to 18.4 months. In addition, enzalutamide can also effectively reduce PSA (prostate-specific antigen) levels. In some patients, PSA has dropped by more than 50% , indicating that tumor growth has been effectively controlled. After using enzalutamide, many patients have experienced relief from cancer-related symptoms such as bone pain and fatigue, and their quality of life has significantly improved.

Another advantage of enzalutamide is that it is relatively well tolerated. Compared with traditional chemotherapy regimens, enzalutamide, as an oral drug, has relatively mild side effects and higher patient compliance. Common adverse reactions include fatigue, high blood pressure, dizziness, headache, etc., but most patients can tolerate it. In addition, some patients may experience an increased risk of epilepsy, cardiovascular events, etc. Therefore, their health status needs to be monitored regularly while taking the medication, and doctors will also adjust the dosage or take preventive measures based on the patient's individual condition.

Overall, enzalutamide demonstrated excellent efficacy in the treatment of prostate cancer, both in chemotherapy-naive patientsmCRPCPatients, as well as those who have already received chemotherapy, can benefit from the drug. It not only prolongs survival, but also significantly improves patients' quality of life, allowing patients with advanced prostate cancer to maintain disease stability for a longer period of time. Although the drug has certain side effects, it still has advantages in safety and tolerability compared with traditional treatment methods, so it is widely recommended for use in the standard treatment plan for prostate cancer.

Reference materials:https://www.xtandi.com/